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Abstract Caveolae are vesicular organelles with a character-
istic uniform diameter in the range of 50^100 nm. Although
recombinant expression of caveolin-1 is sufficient to drive
caveolae formation, it remains unknown what controls the
uniform diameter of these organelles. One hypothesis is that
specific caveolin-caveolin interactions regulate the size of
caveolae, as caveolin-1 undergoes two stages of self-oligomeriza-
tion. To test this hypothesis directly, we have created two
caveolin-1 deletion mutants that lack regions of caveolin-1 that
are involved in directing the self-assembly of caveolin-1
oligomers. More specifically, Cav-1 v61^100 lacks a region of
the N-terminal domain that directs the formation of high
molecular mass caveolin-1 homo-oligomers, while Cav-1 vC
lacks a complete C-terminal domain that is required to allow
caveolin homo-oligomers to interact with each other, forming a
caveolin network. It is important to note that these two mutants
retain an intact transmembrane domain. Our current results
show that although Cav-1 v61^100 and Cav-1 vC are competent
to drive vesicle formation, these vesicles vary widely in their size
and shape with diameters up to 500^1000 nm. In addition,
caveolin-induced vesicle formation appears to be isoform-
specific. Recombinant expression of caveolin-2 under the same
conditions failed to drive the formation of vesicles, while
caveolin-3 expression yielded caveolae-sized vesicles. These
results are consistent with the previous observation that in
transformed NIH 3T3 cells that lack caveolin-1 expression, but
continue to express caveolin-2, no morphologically distinguish-
able caveolae are observed. In addition, as caveolin-2 alone exists
mainly as a monomer or homo-dimer, while caveolins 1 and 3
exist as high molecular mass homo-oligomers, our results are
consistent with the idea that the formation of high molecular
mass oligomers of caveolin are required to regulate the formation
of uniform caveolae-sized vesicles. In direct support of this
notion, regulated induction of caveolin-1 expression in trans-
formed NIH 3T3 cells was sufficient to recruit caveolin-2 to
caveolae membranes. The ability of caveolin-1 to recruit
caveolin-2 most likely occurs through a direct interaction
between caveolins 1 and 2, as caveolins 1 and 2 are normally
co-expressed and interact with each other to form high molecular
mass hetero-oligomers containing both caveolins 1 and 2.
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1. Introduction
Caveolae are 50^100 nm vesicular invaginations of the plas-
ma membrane [1]. They represent a sub-compartment of the
plasma membrane. It has been proposed that caveolae partic-
ipate in vesicular tra⁄cking events and signal transduction
processes. Caveolae are most abundant in terminally di¡er-
entiated cells, such as adipocytes, endothelial cells and muscle
cells [2^7].
The specialized lipid composition of caveolae is thought to
convey resistance of this membrane domain to detergent sol-
ubilization by Triton X-100 (at low temperatures) [3,8^13].
This property appears to be unique to caveolae membranes.
For example, when intact cells were ¢xed in paraformalde-
hyde and extracted with Triton X-100 and then examined
by electron microscopy, the insoluble membranes that re-
mained were found to be caveolae [14].
Caveolin, a 21^24 kDa integral membrane protein, is a
principal component of caveolae membranes in vivo. [15^
19]. Caveolin is only the ¢rst member of a new gene family;
as a consequence, caveolin has been re-termed caveolin-1 [4].
Molecular cloning has identi¢ed three distinct caveolin genes:
caveolin-1, caveolin-2, and caveolin-3. The two isoforms of
caveolin-1 (Cav-1K and Cav-1L) are derived from alternative
initiation during translation. Caveolins 1 and 2 are most
abundantly expressed in adipocytes, endothelial cells and ¢-
broblastic cell types, while the expression of caveolin-3 is
muscle-speci¢c [20^23].
Caveolin proteins interact with themselves to form homo-
and hetero-oligomers [24,25] which directly bind cholesterol
[26], and require cholesterol for insertion into model lipid
membranes [26,27]. These caveolin oligomers may also inter-
act with glycosphingolipids, although the evidence is more
indirect via chemical cross-linking studies [28]. These pro-
tein-protein and protein-lipid interactions are thought to be
the driving force for caveolae formation.
Endogenous caveolin-1 is insoluble in non-ionic detergents
such as Triton X-100 at low temperatures [8,9] ; however, it
can be e⁄ciently solubilized by the mild detergent, octyl-glu-
coside [8,9]. It is thought that octyl-glucoside solubilization
occurs through the displacement of endogenous lipid compo-
nents (such as glycosphingolipids and cholesterol) that are
concentrated within caveolae membranes and interact directly
with caveolin [3,8^13].
Caveolin-1 is a 22^24 kDa integral membrane protein
which consists of 178 amino acid residues. Caveolin-1 assumes
an unusual topology. A central hydrophobic domain (residues
102^134) is thought to form a hairpin-like structure within the
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membrane (reviewed in [29,30]). As a consequence, both the
N-terminal domain (residues 1^101) and the C-terminal do-
main (residues 135^178) face the cytoplasm. Caveolin-1
undergoes two stages of self-oligomerization. In the ¢rst stage,
a 41 aa region of the N-terminal domain (residues 61^101)
directs the formation of caveolin homo-oligomers [24]. Later,
in the second stage, the 44 aa C-terminal domain acts as a
bridge to allow these homo-oligomers to interact with each
other thereby forming a caveolin-rich sca¡old or lattice-work
within the plane of the membrane [31].
A number of investigators have puri¢ed ‘caveolae’ from
cells and tissues that lack apparent expression of caveolins
[32^34]. These membranes were puri¢ed based on their Triton
insolubility and light buoyant density in sucrose gradients;
they have also been puri¢ed based simply on their light buoy-
ant density in the absence of detergents. These domains have
been termed Triton-insoluble complexes, detergent-resistant
membranes, low-density membranes, and caveolae-related do-
mains (CRDs). Like caveolae, these microdomains are dra-
matically enriched in cholesterol, sphingolipids, and lipid-
modi¢ed signaling molecules [32,33].
These CRDs can also be produced in vitro simply by mix-
ing cholesterol, sphingolipids, and phospholipids in the appro-
priate ratio [33]. Their Triton insolubility is apparently a phys-
ical property of their molecular organization that produces a
liquid-ordered membrane domain (rather than £uid or liquid-
crystalline). As caveolin-1 is found associated with glycosphin-
golipids in vivo as shown using chemical cross-linking with a
radio-labeled glycosphingolipid GM1 [28], binds cholesterol
directly [26], and requires a high local concentration of cho-
lesterol (s 30%) to insert into model lipid membranes in vitro
[26,27], these ¢ndings suggest that a true functional relation-
ship exists between CRDs and mature caveolae. For example,
during the biogenesis of mature caveolae, CRDs would need
to exist as precursors to facilitate the proper insertion of cav-
eolins into membranes. Thus, in cells that express caveolins,
these CRDs may represent ‘pre-caveolae’ that simply lack
caveolin proteins. In support of this reductionist model, re-
combinant expression of caveolin-1 in cells that lack morpho-
logically detectable caveolae is su⁄cient to drive the forma-
tion of mature invaginated caveolae [35^37]. This indicates
that cells normally make the ingredients that are necessary
for the formation of mature caveolae and insertion of caveolin
proteins may be only a late phase in this process. However, it
remains unknown whether expression of caveolin-2 or caveo-
lin-3 is su⁄cient to drive caveolae formation.
Here, we have performed a mutational analysis to deter-
mine if speci¢c caveolin-caveolin interactions are required to
regulate the size of caveolae, as caveolin-1 undergoes two
stages of self-oligomerization. To test this hypothesis directly,
we have created two caveolin-1 deletion mutants that lack
regions of caveolin-1 that are involved in directing the self-
assembly of caveolin-1 oligomers. Our current results show
that although these mutants are competent to drive vesicle
formation, these vesicles vary widely in their size and shape
with diameters up to 500^1000 nm. In addition, we show that
caveolin-induced vesicle formation appears to be isoform-spe-
ci¢c. Recombinant expression of caveolin-2 under the same
conditions failed to drive the formation of vesicles, while cav-
eolin-3 expression yielded caveolae-sized vesicles. As caveolin-
2 exists mainly as a monomer or homo-dimer, while caveolins
1 and 3 exist as high molecular mass homo-oligomers, our
results are consistent with the idea that the formation of
high molecular mass oligomers of caveolin are required to
regulate the formation of uniform caveolae-sized vesicles in
vivo. This is the ¢rst demonstration that the ability to drive
the formation of a uniform population of vesicles (50^100 nm
in diameter) is unique to caveolins 1 and 3 and requires the
ability of caveolin-1 to oligomerize correctly.
2. Materials and methods
2.1. Materials
The cDNAs for caveolins 1, 2 and 3 were as we described previ-
ously [4,8,20,22]. Antibodies and their sources were as follows: anti-
caveolin-1 (mAb 2297, generous gift of Dr. John R. Glenney, Jr.,
Transduction Labs); anti-caveolin-2 (mAb 65; Transduction Labs
[20]); anti-caveolin-3 (mAb 26; Transduction Labs [21]); and anti-
myc (mAb 9E10; Santa Cruz Biotech). The baculovirus expression
system was from Clontech: a transfer plasmid vector pBacPAK9
and an engineered baculovirus vector BacPAK6. Normal and Ras-
transformed NIH 3T3 cell lines were as we described previously
[37,38].
2.2. Insect Sf21 cell culture
Insect Spodoptera frugiperda (Sf21) cells were provided by Dr. Ta-
kashi Okamoto (Cleveland Clinic Foundation). Sf21 cells were grown
in Ex-cell 401 medium containing 10% fetal bovine serum and anti-
biotics (penicillin-streptomycin) at 27‡C.
2.3. Construction of recombinant baculoviruses
cDNAs encoding caveolin-1, caveolin-1 mutants, caveolin-2 and
caveolin-3 were subcloned into the multiple cloning site of a transfer
plasmid vector, pBacPAK9. A mixture of 2 Wg of recombinant plas-
mid pBacPAK 9 DNA and 1 Wg of puri¢ed engineered baculoviral
vector DNA BacPAK 6 (Bsu36I digest) (Clontech) were transfected
into insect Sf21 cells, as suggested by the manufacturer [39]. Four
days later, culture supernatants were removed and centrifuged at
1000 rpm for 10 min. Clari¢ed supernatants containing wild-type
and recombinant baculoviruses were plaque assayed on a monolayer
of Sf21 cells. Occlusion negative plaques were picked and seeded onto
2.5U106 cells. After 3 days incubation, cells and culture supernatants
were removed and centrifuged at 1000 rpm for 10 min. The cell pellets
were analyzed by immunoblotting analysis using anti-caveolin anti-
bodies or anti-myc tag mAb 9E10. Those plaques testing positive for
the presence of caveolins were selected for three rounds of plaque
puri¢cation. The selected plaques with highest yield of expression
were used as recombinant baculovirus stock for producing protein
by infecting insect Sf21 cells.
2.4. Immunoblotting
The expression of caveolins in the baculovirus expression system
was evaluated by SDS-PAGE and Western blot analysis. For detec-
tion, samples were separated using SDS-PAGE (10% or 15% acryl-
amide) and transferred to nitrocellulose for primary antibody binding
(anti-caveolin antibodies or anti-myc mAb 9E10). HRP-conjugated
secondary antibodies (1:5000 dilution, Amersham) were used to vis-
ualize bound primary antibodies by an enhanced chemiluminescence
assay (ECL; Amersham).
2.5. Electron microscopy
Transmission electron microscopy was performed as described pre-
viously by our laboratory. Samples were ¢xed with glutaraldehyde,
post¢xed with osmium tetroxide, and stained with uranyl acetate and
lead citrate, as detailed in [8,10]. Samples were examined under the
Philips 410 TEM.
2.6. Triton insolubility
The Triton solubility of a given protein was determined essentially
as we described previously, with minor modi¢cations [9]. Brie£y, NIH
3T3 cells grown to con£uence in 35 mm dishes were ¢rst extracted
with 1 ml of MES-bu¡ered saline (MBS, 25 mM MES, pH 6.5, 0.15 M
NaCl) containing 1% Triton X-100 and 1 mM PMSF. After 30 min
on ice without agitation, the Triton-soluble extract (S) was gently
decanted and the remaining Triton-insoluble material (I) was solubi-
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lized in 1 ml of 1% SDS. Each extract was then concentrated by
acetone precipitation, solubilized in 10% SDS, and diluted into
4Usample bu¡er for analysis by SDS-PAGE and Western blotting.
2.7. Cell fractionation
NIH 3T3 cells were grown to con£uence in 150 mm dishes and used
to prepare caveolin-enriched membrane fractions, essentially as de-
scribed [3,8,10,40]. Brie£y, NIH 3T3 cells from a con£uent 150 mm
dish were scraped into 2 ml of MBS containing 1% Triton X-100 and
1 mM PMSF. Homogenization was carried out with 10 strokes of a
loose-¢tting Dounce homogenizer. The homogenate was adjusted to
40% sucrose by addition of 2 ml of 80% sucrose prepared in MBS and
placed at the bottom of an ultracentrifuge tube. A 5^30% linear su-
crose gradient was formed above the homogenate and centrifuged at
39 000 rpm for 16^20 h in a SW41 rotor (Beckman Instruments, Palo
Alto, CA). A light-scattering band con¢ned to the 15^20% sucrose
region is harvested, diluted 3-fold with MBS and pelleted in the mi-
crofuge (14 000Ug ; 15 min at 4‡C). The majority of protein remained
within the 40% sucrose region of the gradient. Approximately 4^6 Wg
of caveolin-enriched domains were obtained from one 150 mm dish of
cells representing 10 mg of protein, a yield of V0.05% relative to the
homogenate. We and other laboratories have demonstrated that these
domains exclude a variety of organelle-speci¢c membrane markers
(for ER, Golgi, lysosomes, mitochondria and non-caveolar plasma
membrane), but are dramatically enriched V2000-fold in caveolin-1,
a caveolar marker protein [3,8,10,13,40,41].
3. Results
3.1. Baculovirus-based expression of wild-type caveolin-1 and
caveolin-1 mutants in Sf21 insect cells
Full-length caveolin-1 or a variety of caveolin-1 mutants
(Y14F, v61^100, and vC) were integrated into an engineered
baculovirus genome via a recombinant transfer plasmid, as
detailed in Section 2. For these constructions, a myc epitope
tag was placed at the C terminus with a polyhistidine tag
following the myc tag (Fig. 1).
Wild-type caveolin-1 and caveolin-1 mutants were all ex-
pressed very well in Sf21 insect cells using the baculovirus
system. Fig. 2A shows that wild-type caveolin-1 and caveo-
lin-1 mutants migrated at their expected molecular weight,
including the myc and polyhistidine tags. We and others
have previously shown that these tags do not interfere with
the targeting of recombinant caveolins or the ability of cav-
eolin-1 expression to drive vesicle formation [4,19,22,36,42^
45]. In addition, expression of caveolin-1 in insect cells using
the baculovirus system allowed the expression of V50^100-
fold more caveolin-1 protein, as compared with a mammalian
cell line (NIH 3T3) that normally expresses caveolin-1 (Fig.
2B).
Electron microscopic analysis of uninfected Sf21 insect cells
did not show the appearance of caveolae, as we have reported
previously [36] (Fig. 3A). However, insect cells infected with
wild-type full length caveolin-1 accumulated a uniform pop-
ulation of caveolae-like structures within their cytoplasm. This
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Fig. 2. Expression of full-length caveolin-1 and caveolin-1 mutants in Sf21 insect cells. A: Lysates from insect cells infected with a given bacu-
lovirus vector were prepared and subjected to immunoblot analysis with a monoclonal antibody probe that recognizes the myc epitope (mAb
9E10). B: Lysates from NIH 3T3 cells and insect cells expressing caveolin-1 were compared by Western blot analysis using a caveolin-1-speci¢c
monoclonal antibody probe (2297). Note that expression of caveolin-1 in insect cells using the baculovirus system allowed the expression of
V50^100-fold more caveolin-1 protein, as compared with a mammalian cell line (NIH 3T3 cells). Uninfected Sf21 cells served as a negative
control. Each lane contains equal amounts of total protein.
Fig. 1. Construction of caveolin-1 mutants for expression in Sf21 in-
sect cells. Full-length caveolin-1 (FL), a tyrosine-to-phenylalanine
point mutant (Y14F), an internal deletion mutant lacking the oligo-
merization domain (v61^100), and a mutant lacking a complete C-
terminal domain (vC) are shown. Note that all constructs contain a
C-terminal myc tag, followed by a polyhistidine tag.
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population of vesicles was homogeneous in size and is the
same size as expected for mammalian caveolae, V50^100
nm in diameter (Fig. 3B). Virtually identical results were ob-
served with caveolin-1 Y14F, indicating that tyrosine phos-
phorylation of this residue is not required for caveolin-1-in-
duced vesicle formation (not shown). Src tyrosine kinases are
known to phosphorylate caveolin-1 on tyrosine 14 both in
vitro and in vivo [46].
Both caveolin-1 mutants, v61^100, and vC, also retained
the ability to drive vesicle formation (Fig. 3C,D). However,
these vesicles varied widely in their size and shape with diam-
eters up to 500^1000 nm. As these two mutants lack speci¢c
regions of caveolin-1 that have been implicated in caveolin-1
oligomerization, it appears that these caveolin-caveolin inter-
actions may be necessary to regulate the uniform 50^100 nm
diameter that is characteristic of caveolae in vivo.
3.2. Caveolin-induced vesicle formation is isoform-speci¢c:
expression of caveolin-2 does not drive vesicle formation
As previous reports have only examined the ability of cav-
eolin-1 to drive the formation of caveolae and caveolin-in-
duced vesicles, we next assessed the ability of caveolin-2 and
caveolin-3 to drive vesicle formation. Caveolins 1 and 2 are
usually co-expressed and demonstrate the same tissue distri-
bution [4,20] ; in contrast, the expression of caveolin-3 is con-
¢ned to muscle cell types (smooth, cardiac and skeletal) [21^
23]. Interestingly, caveolins 1 and 3 assemble into high mo-
lecular mass homo-oligomers of V350 kDa [22,24]. On the
other hand, caveolin-2 primarily exists as a monomer or dimer
and requires caveolin-1 co-expression to assemble into a high
molecular mass complex of V350 kDa [4,20].
Caveolins 1, 2, and 3 were all equally well expressed in Sf21
insect cells infected with a given baculovirus (Fig. 4). Electron
microscopic analysis revealed that cells infected with either
caveolin-1 or caveolin-3 accumulated a uniform population
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Fig. 3. Morphological analysis of caveolin-induced vesicle formation. Sf21 insect cells were infected with either full-length caveolin-1 or a given
caveolin-1 mutant. Cells were ¢xed and processed for transmission electron microscopy. A: Uninfected control cells lacking caveolin-1 induced
vesicles. B: Infected Sf21 cells expressing caveolin-1 FL contain a uniform population of caveolin-1-induced vesicles of V50^100 nm in diame-
ter. C: Infected Sf21 cells expressing caveolin-1 (v61^100). D: Infected Sf21 cells expressing caveolin-1 (vC). Note that in panels C and D, cav-
eolin-1-induced vesicles were produced, but they have a much larger diameter and are irregular in size and shape. Bar = 100 nm.
Fig. 4. Expression of full-length caveolins 1, 2 and 3 in Sf21 insect
cells. Lysates from insect cells infected with a given baculovirus vec-
tor were prepared and subjected to immunoblot analysis with a
monoclonal antibody probe that recognizes the myc epitope (mAb
9E10). Note that all three caveolins were equally well expressed us-
ing this approach.
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of caveolae-like structures within their cytoplasm (Fig. 5).
This population of vesicles was homogeneous in size, with a
diameter of V50^100 nm. In contrast, expression of caveolin-
2 did not drive vesicle formation, despite evidence of infection
such as viral particles (Fig. 5). These results indicate that a
transmembrane domain alone is not su⁄cient to drive vesicle
formation in Sf21 insect cells.
Co-infection of insect cells with baculoviruses encoding cav-
eolins 1 and 2 also resulted in the formation of a uniform
population of caveolae-like structures. However, these vesicles
appeared smaller in size, with a diameter of V45^65 nm (Fig.
6). These results indicate that interactions between caveolins 1
and 2 can also serve to regulate the diameter of caveolae-like
vesicles.
3.3. Caveolin-1 recruits caveolin-2 to caveolae membranes
NIH 3T3 cells co-express caveolins 1 and 2 where they form
a stable hetero-oligomeric complex in vivo and both are tar-
geted to caveolae membranes [20]. However, in NIH 3T3 cells
transformed by activated oncogenes, such as activated Ras
(G12V), caveolin-1 mRNA and protein expression are selec-
tively down-regulated [37]. Under these conditions, caveolin-2
protein levels remain relatively constant [20]. Thus, we com-
pared the properties of caveolin-2 in normal and Ras-trans-
formed NIH 3T3 cells to assess the e¡ects of caveolin-1 down-
regulation on the behavior and localization of caveolin-2.
There are now three recognized isoforms of caveolin-2 (K,
L, and Q). Cav-2K and Cav-2L are thought to be generated by
from a single mRNA species using alternative translation ini-
tiation sites (M1 and M13), while the origin and primary
sequence of Cav-2Q remains unknown ([20] ; and unpublished
observations). Interestingly, Cav-2Q is abundantly expressed in
astrocytes (data not shown).
Fig. 7A shows that loss of caveolin-1 expression in Ras-
transformed NIH 3T3 cells results in the selective down-reg-
ulation of both Cav-2L and Cav-2Q isoforms, while the levels
of Cav-2K remain relatively constant. In addition, in the ab-
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Fig. 6. Caveolae-like vesicles are smaller in cells co-infected with
caveolin-1 and caveolin-2. Co-infection of insect cells with baculovi-
ruses encoding caveolins 1 and 2 also resulted in the formation of a
uniform population of caveolae-like structures. However, these
vesicles appeared smaller in size, with a diameter of V45^65 nm.
These results indicate that interactions between caveolins 1 and 2
can also serve to regulate the diameter of caveolae-like vesicles. Left
panel, caveolin-1 alone; right panel, caveolin-1 plus caveolin-2.
Bar = 100 nm.
Fig. 5. Expression of caveolin-2 fails to drive caveolin-induced vesicle formation in Sf21 insect cells. A: Uninfected control cells. B: Cells in-
fected with caveolin-1. C: Cells infected with caveolin-2. D: Cells infected with caveolin-3. Note that expression of caveolins 1 and 3 (panels B
and D) is su⁄cient to drive the formation of a uniform population of caveolin-induced vesicles with a diameter of 50^100 nm. In contrast, ex-
pression of caveolin-2 (panel C) does not drive vesicle formation, despite evidence of infection such as viral particles (which appear as short
and long black bar-like structures). Bar = 100 nm.
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sence of caveolin-1 expression, all three caveolin-2 isoforms
appeared to become predominantly Triton-soluble (V60^
100%), while all three caveolin-2 isoforms were s 90% Tri-
ton-insoluble in normal NIH 3T3 cells which express caveolin-
1 (Fig. 7B). These results suggest that the stability and Triton-
insolubility of caveolin-2 isoforms may be dependent on co-
expression with caveolin-1. As caveolae and CRDs are Triton-
insoluble membrane compartments [3,8^13], these results also
suggest that caveolin-2 requires caveolin-1 to localize to these
cholesterol/sphingolipid-rich microdomains.
To test this hypothesis directly, we next utilized a Ras-
transformed NIH 3T3 cell line that harbors caveolin-1 under
the control of an inducible promoter. In this previously char-
acterized cell line, recombinant caveolin-1 can be induced by
addition of the simple sugar IPTG to the culture medium [37].
We analyzed the distribution of caveolin-1 and -2 in this cell
line using an established biochemical procedure that separates
caveolae and CRDs from the bulk of cellular membranes and
cytosolic proteins [3,8,10,13,40,41,43,47^50]. In this fractiona-
tion scheme, immunoblotting with anti-caveolin-1 IgG can be
used to track the position of caveolae-derived membranes
within these bottom-loaded sucrose gradients. Using this pro-
cedure, caveolin-1 is puri¢ed V2000-fold relative to total cell
lysates as V4^6 Wg of caveolin-rich domains (containing
V90^95% of total cellular caveolin-1) are obtained from 10
mg of total cellular proteins [41,48]. We and others have
shown that these caveolin-rich fractions exclude s 99.95%
of total cellular proteins and also markers for non-caveolar
plasma membrane, Golgi, lysosomes, mitochondria and endo-
plasmic reticulum [3,8,10].
Fig. 8A shows that recombinant caveolin-1 was correctly
targeted to caveolae membranes (fractions 4 and 5) after in-
ducing its expression by incubation with IPTG. Interestingly,
in the absence of caveolin-1 induction, only V40^50% of
Cav-2K was targeted to caveolae membranes, while Cav-2L
was completely excluded from caveolae membranes and
Cav-2Q was undetectable. In contrast, after induction of cav-
eolin-1 expression, all three caveolin-2 isoforms were predom-
inantly localized to caveolae and Cav-2L and Cav-2Q were
upregulated (Fig. 8B). As caveolins 1 and 2 are known to
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Fig. 7. Down-regulation of caveolin-1 a¡ects the expression and detergent insolubility of caveolin-2 isoforms. A: Expression of caveolin-1 and
caveolin-2 isoforms (K, L, and Q) in normal and Ras-transformed NIH 3T3 cells. B: Detergent insolubility of caveolin-2 isoforms (K, L, and Q)
in normal and Ras-transformed NIH 3T3 cells. I, Triton-insoluble; S, Triton-soluble. Each lane contains equal amounts of total protein. Cav-
eolins 1 and 2 were detected by Western blot analysis using mono-speci¢c antibody probes: anti-caveolin-1 IgG (mAb 2297) and anti-caveolin-
2 (mAb 65). In A and B, multiple exposures are shown to illustrate the di¡erent isoforms of caveolin-2. Note that Cav-2L is much less abun-
dant than Cav-2K and Cav-2Q is the least abundant isoform.
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form a large hetero-oligomeric complex in vivo [20,24], our
results clearly indicate that caveolin-1 expression stabilizes
and recruits caveolin-2 isoforms to caveolae membranes.
These results are also consistent with our morphological
observations in insect cells : (i) that caveolin-2 expression
alone is not su⁄cient to generate caveolae-like vesicles; and
(ii) that co-expression of caveolins 1 and 2 in insect cells yields
the formation of caveolae-like vesicles that are of a smaller
diameter than those generated using caveolin-1 alone. Taken
together, these observations suggest that caveolin-2 may func-
tion as an ‘accessory protein’ in conjunction with caveolin-1.
4. Discussion
We have previously developed a functional assay system to
monitor the ability of caveolin-1 expression to drive the for-
mation of a uniform population of caveolae-sized vesicles [36].
In this system, Sf21 insect cells were infected with a baculo-
virus vector encoding caveolin-1K (residues 1^178) or caveo-
lin-1L (residues 32^178) and examined by transmission elec-
tron microscopy. Results of these studies indicated that
recombinant expression of caveolin-1 is su⁄cient to drive
vesicle formation and that residues 1^32 of caveolin-1 are
not required for this process [36]. As cholesterol and sphingo-
lipids are important lipid components of caveolae membranes
in mammalian cells, it is important to note that insect cells
also use sphingolipids and plasma membrane sterols, includ-
ing cholesterol [51,52].
Here, we have employed this morphological assay system to
perform a mutational analysis of the ability of caveolin-1 to
drive the formation of caveolae-sized vesicles. We have shown
that caveolin-1 deletion mutants (v61^100 and vC), lacking
either the N-terminal oligomerization domain or the extreme
C-terminal domain, are su⁄cient to drive vesicle formation.
However, these vesicles are larger and appear irregular in their
size and shape. Additionally, we show that while caveolins 1
and 3 are competent to drive vesicle formation, caveolin-2
expression fails to drive the formation of any vesicles (regular
or irregular). Thus, the ability to drive the formation of a
uniform population of vesicles (50^100 nm in diameter) is
unique to caveolins 1 and 3 and requires the ability of cav-
eolin-1 to oligomerize correctly.
As caveolin-2 fails to drive vesicle formation, this should
be extremely useful in future mutational studies aimed at
determining which regions of caveolin-1 are su⁄cient to allow
caveolin-2 to drive vesicle formation. For example, such a
study could be carried out by constructing a panel of chimeric
proteins containing regions of both caveolin-1 and caveolin-
2.
Recently, we have reported that the co-expression of cav-
eolins 1 and 2 is uncoupled by cellular transformation by
activated oncogenes, such as v-Abl and activated H-Ras
(G12V). While caveolin-1 mRNA and protein levels are
down-regulated in response to cellular transformation [38],
caveolin-2 protein levels remain relatively unchanged [20].
While these cells continue to express caveolin-2 protein, they
fail to contain detectable caveolae, as we have reported pre-
viously [38]. These observations suggest that caveolin-2 ex-
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Fig. 8. Induction of caveolin-1 expression recruits caveolin-2 isoforms to caveolae membranes. A: Distribution of total cellular proteins (visual-
ized by Ponceau S staining) and caveolin-1. Note that recombinant caveolin-1 was correctly targeted to caveolae membranes (fractions 4 and 5)
after inducing its expression by incubation with IPTG. B: Distribution of caveolin-2 isoforms (K, L, and Q) before and after induction of the
expression of recombinant caveolin-1 using IPTG. Note that in the absence of caveolin-1 induction, only V40^50% Cav-2K was targeted to
caveolae membranes (fractions 4 and 5), while Cav-2L was completely excluded from caveolae membranes and Cav-2Q was undetectable. In
contrast, after induction of caveolin-1 expression, all three caveolin-2 isoforms were predominantly localized to caveolae (fractions 4 and 5) and
Cav-2L and Cav-2Q were upregulated. Caveolins 1 and 2 were detected by Western blot analysis using mono-speci¢c antibody probes: anti-cav-
eolin-1 IgG (mAb 2297) and anti-caveolin-2 (mAb 65). In panel B, multiple exposures are shown to illustrate the di¡erent isoforms of caveolin-
2. Fractions 1^3 have been omitted as they do not contain any protein or caveolin isoforms, as we and others have indicated in previous re-
ports [3,8,10,13,40,41].
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pression alone is not su⁄cient to drive the formation of mor-
phologically detectable caveolae.
In support of this idea, we show here that expression of
caveolin-2 in Sf21 insects cells fails to drive the formation of
caveolae-like vesicles, while recombinant expression of caveo-
lin-1 within the same cell system is su⁄cient to drive the for-
mation of hundreds of uniform caveolae-like vesicles (50^100
nm in diameter). In addition, we demonstrate that: (i) co-
expression of caveolins 1 and 2 in insect cells yields the for-
mation of caveolae-like vesicles that are of a smaller diameter
than those generated using caveolin-1 alone; and (ii) caveolin-
1 expression in mammalian cells stabilizes and recruits caveo-
lin-2 isoforms to caveolae membranes. Our results are consis-
tent with the idea that caveolin-2 expression alone is not suf-
¢cient to drive caveolae formation and that caveolin-2 may
function as an ‘accessory protein’ in conjunction with caveo-
lin-1.
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